Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dong-A Faces Price Hit As Korea Ups Fight Against Illegal Rebates

Executive Summary

In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.

Advertisement

Related Content

Korea Revises Rules To Curb Rebate Activities, Improve Ethics
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
More Action Against Novartis As Korea FTC Issues Fine For Unfair Promotion
Novartis Slapped With New $49m Fine For Korea ‘Rebates’
Novartis Korea Hit With Fine, Product Suspensions Over Illegal ‘Rebates’
Price Cuts For Daewoong As Korea Attacks Rebates
Twelve Indicted In $4.53 Million Rebate Case Involving Korea’s Dong-A

Topics

Advertisement
UsernamePublicRestriction

Register

SC099198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel